VRTX Share Price

Open 136.58 Change Price %
High 137.00 1 Day -2.03 -1.50
Low 132.12 1 Week 10.36 8.41
Close 133.50 1 Month 15.70 13.33
Volume 2172143 1 Year 51.60 63.00
52 Week High 137.26
52 Week Low 71.46
VRTX Important Levels
Resistance 2 138.02
Resistance 1 136.16
Pivot 134.21
Support 1 130.84
Support 2 128.98
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VRTX Technical Analysis 5
As on 23rd Jun 2017 VRTX Share Price closed @ 133.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 95.78 & Strong Buy for SHORT-TERM with Stoploss of 120.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRTX Target for June
1st Target up-side 129.12
2nd Target up-side 132.98
3rd Target up-side 136.85
1st Target down-side 118.08
2nd Target down-side 114.22
3rd Target down-side 110.35
VRTX Other Details
Segment EQ
Market Capital 9959515136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vrtx.com
VRTX Address
VRTX
50 Northern Avenue
Boston, MA 02210
United States
Phone: 617-341-6100
Interactive Technical Analysis Chart Vertex Pharmaceuticals Incorporated ( VRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vertex Pharmaceuticals Incorporated
VRTX Business Profile
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.